Antiplatelet agents for chronic kidney disease

Author:

Natale Patrizia123,Palmer Suetonia C4,Saglimbene Valeria M12,Ruospo Marinella12,Razavian Mona5,Craig Jonathan C26,Jardine Meg J7,Webster Angela C28,Strippoli Giovanni FM126

Affiliation:

1. Department of Emergency and Organ Transplantation; University of Bari; Bari Italy

2. Sydney School of Public Health; The University of Sydney; Sydney Australia

3. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy

4. Department of Medicine; University of Otago Christchurch; Christchurch New Zealand

5. Renal and Metabolic Division; The George Institute for Global Health; Newtown Australia

6. Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia

7. NHMRC Clinical Trials Centre; Camperdown Australia

8. Centre for Transplant and Renal Research, Westmead Millennium Institute; The University of Sydney at Westmead; Westmead Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference686 articles.

1. Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065];Goicoechea;Journal of the American Society of Nephrology,2017

2. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study);Goicoechea;Cardiovascular Drugs & Therapy,2018

3. Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186];Goicoechea;Journal of the American Society of Nephrology,2017

4. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients;Goicoechea;Prostaglandins Leukotrienes & Essential Fatty Acids,2017

5. Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study;Abacilar;Indian Journal of Nephrology,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3